Kenaitinib

克耐替尼

Report date: 2023/05/05 17:41:29
NME

Base Information

Drug NameKenaitinib
Drug Alias NameKeynatinibMED-1007TL-007
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR T790M inhibitors
TargetsEGFR T790M
Therapy Area/IndicationsBrain metastasesCentral Nervous System LymphomaCarcinoma, Non-Small-Cell Lung +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesJiangsu Maidu Pharmaceutical R & D Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesMedolution LtdJiangsu Maidu Pharmaceutical R & D Co Ltd
Inactive CompaniesN/A
Active IndicationsBrain metastasesCentral Nervous System LymphomaCarcinoma, Non-Small-Cell Lung +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A